免疫組織化学（IHC）市場規模、セグメント分析、2030年までの世界予測

この調査レポートでは、免疫組織化学（IHC）市場を製品とサービス、製品（抗体[一次抗体、二次抗体]、[クローン性{モノクローナル、ポリクローナル}]、[規制クラス{クラスI/IIアッセイ抗体、クラスIIIアッセイ抗体}]、試薬[ブロッキング血清および試薬、発色基質、固定試薬、希釈剤、有機溶媒、タンパク質分解酵素、その他の試薬]、キット[ヒト免疫組織化学キット、動物免疫組織化学キット]、機器とソフトウェア（IHC染色装置）、[サンプル調製機器{組織処理装置、ミクロトーム、その他のサンプル調製機器}]、（画像分析機器）、サービス、アプリケーション（診断アプリケーション[がん、感染症、腎臓疾患、自己免疫疾患、神経疾患、その他の疾患]、研究アプリケーション[医薬品開発および試験、その他の研究アプリケーション]、法医学アプリケーション}、エンドユーザー（病院・診断研究所、学術・研究機関・契約研究機関、その他のエンドユーザー）、サービスのエンドユーザー（製薬・バイオテクノロジー企業・学術機関）、地域（北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ）別に分析しています。本レポートは、免疫組織化学市場の成長に影響を与える推進要因、課題、機会、制約など、主要な要因に関する詳細な情報を網羅しています。主要業界プレーヤーの詳細な分析により、事業概要、サービスポートフォリオ、コラボレーション、パートナーシップ、拡張、契約、買収などの主要戦略、そして免疫組織化学市場に関連する最近の動向に関する洞察を提供しています。本レポートは、免疫組織化学市場エコシステムにおける主要プレーヤーと新興企業の競合分析を網羅しています。

本レポートは、免疫組織化学（IHC）市場の成長に影響を与える主要な要因（促進要因、制約要因、課題、機会など）に関する詳細な情報を網羅しています。主要業界プレーヤーを徹底的に分析し、事業概要、ソリューション、サービス、主要戦略、新製品・新サービスの発売、買収、そして免疫組織化学市場に関連する最近の動向に関する洞察を提供しています。本レポートは、免疫組織化学市場エコシステムにおける新興企業の競合分析を網羅しています。

免疫組織化学（IHC）市場は、2024年の35億5,000万米ドルから2030年には51億4,000万米ドルに達し、予測期間中は年平均成長率（CAGR）7.6%で成長すると予測されています。

市場の成長を牽引する要因としては、増加する高齢者人口におけるがん罹患率の増加と、がんの診断および管理における免疫組織化学（IHC）検査の適用拡大が挙げられます。さらに、コンパニオン診断（CDx）の開発と、個別化医療開発に向けたIHC技術との統合も、市場の拡大を後押ししています。

The immunohistochemistry market is expected to reach USD 5.14 billion in 2030 from USD 3.55 billion in 2024, at a CAGR of 7.6% during the forecast period. Factors propelling the growth of the market are the increased prevalence of cancer cases among the growing geriatric population and the rising application of IHC tests for the diagnosis and management of cancer. Moreover, the development of companion diagnostics (CDx) and its integration with IHC technology to develop personalized medicine further support the expansion of the market.

The histological stain segment accounted for the largest share of the immunohistochemistry reagents segment in 2024.

The market is segmented into histological stains, blocking sera and reagents, chromogenic substrates, fixation reagents, diluents, organic solvents, proteolytic enzymes, and other reagents. In 2024, the histological stains segment accounted for the largest share of the immunohistochemistry market. This is due to their primary application being in immunohistochemistry, a powerful technique where stains are used to visualize and differentiate specific cellular components, proteins, and structures within tissue samples by leveraging antigen-antibody interactions. This allows for the precise localization of biomarkers critical for diagnosis and research. Furthermore, the utility of histological stains is expanding through advanced techniques like multiplex staining, also known as multiple staining. This method employs several stains simultaneously to detect multiple targets within a single tissue section. This is particularly valuable in fields like immuno-oncology as it conserves precious patient samples while providing a comprehensive view of the complex tumor microenvironment. A major driver for this market remains its pivotal function in cancer diagnosis, where pathologists use these stains to distinguish between normal and abnormal tissue morphology, thereby determining tumor grade and type.

In 2024, by application, the research applications segment accounted for the second-largest share of the market.

The immunohistochemistry market is segmented into diagnostic applications, research applications, and forensic applications. In 2024, the research applications segment accounted for the second-largest share of the immunohistochemistry market. IHC technology is a cornerstone of modern biomedical investigation, particularly in anti-tumor drug development and biomarker discovery. It provides researchers with an unparalleled ability to visualize the expression and precise subcellular location of specific proteins within the contextual architecture of tissue. This is fundamental to understanding the complex cellular mechanisms that underpin cancer and other diseases. For instance, in the exploration of the cancer proteome, IHC is instrumental for validating new drug targets identified through genomic or proteomic screening, confirming their presence and relevance in actual tumor tissues. The role of IHC in research extends across numerous scientific disciplines. In developmental biology and embryological studies, it allows for mapping key regulatory proteins during different stages of development, offering insights crucial for understanding morphogenesis and congenital disorders. Similarly, in stem cell research, IHC is used to monitor markers of proliferation and differentiation, providing essential data on stem cell behavior and therapeutic potential. The continuous investment in R&D by pharmaceutical and biotechnology companies, coupled with the global push towards personalized medicine, ensures that the research application segment will remain a dynamic and expanding component of the immunohistochemistry market.

.

In 2024, North America accounted for the largest share of the immunohistochemistry market.

North America accounted for the largest share of the immunohistochemistry market in 2024. This leadership position is underpinned by various factors, including the region’s highly advanced healthcare infrastructure, substantial healthcare expenditure, and the robust presence of key market players and leading research institutions. The US, in particular, serves as the primary driver of this growth, fueled by a high prevalence of chronic diseases, most notably cancer. The significant and rising incidence of various cancers necessitates sophisticated and accurate diagnostic tools, with IHC being a cornerstone of modern pathology for tumor classification and biomarker analysis. Furthermore, the region benefits from extensive government and private funding for biomedical research and development, which accelerates the adoption of innovative IHC technologies and automated platforms. Favorable reimbursement policies and a high level of awareness among clinicians and patients regarding advanced diagnostic options also contribute to the market’s expansion. The strong regulatory framework, while stringent, ensures the quality and reliability of IHC products, fostering trust and widespread use in both clinical diagnostics and the burgeoning pharmaceutical and biotechnology research sectors, solidifying the preeminent standing of North America in the global IHC landscape.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
• By Designation: C-level Executives – 55%, Directors- 20%, and Others- 25%
• By Region: North America -45%, Europe – 20%, Asia Pacific -20%, Latin America -10%, the Middle East- 3%, and Africa-2%

Hoffmann-La Roche Ltd (Switzerland), Danaher Corporation (US), Agilent Technologies, Inc. (US), Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Bio-Rad Laboratories, Inc. (US), Bio-Techne (US), Becton, Dickinson and Company (US), Takara Bio Inc. (Japan), PHC Holdings Corporation (Japan), Enzo Biochem Inc. (US), Sino Biological, Inc. (China), OriGene Technologies, Inc. (US), Cell Signaling Technology, Inc. (US), Bio SB (US), Miltenyi Biotec (Germany), Sakura Finetek (US), EagleBio (US), Biocare Medical LLC (US), Elabscience BioInnovation Inc. (US), Bio-Genex (US), Diagnostic BioSystems Inc. (US), Histo-Line Laboratories (Italy), Rockland Immunochemicals, Inc. (US), and CANDOR Bioscience GmbH (Germany) are some of the key companies offering immunohistochemistry products.

Research Coverage

This research report categorizes the immunohistochemistry market by Product & Service, Product (Antibodies [Primary antibodies, secondary antibodies], [Clonality {Monoclonal, Polyclonal}], [Regulatory Class {Class I/II Assay Antibodies, Class III Assay Antibodies}], Reagents [blocking sera and reagents, chromogenic substrates, fixation reagents, diluents, organic solvents, proteolytic enzymes, other reagents], Kits [Human Immunohistochemistry Kits, Animal Immunohistochemistry Kits], Instruments & Software (IHC Stainers), [Sample Preparation Instruments {Tissue Processors, Microtomes, Other Sample Preparation Instruments}], (Image Analysis Instruments), Service, Application (Diagnostic Applications [Cancer, Infectious Diseases, Nephrological Diseases, Autoimmune Diseases, Neurological Diseases, Other Diseases] Research Applications [Drug Development and testing, Other Research Applications], Forensic Applications}, End User for Product (Hospitals & Diagnostic Laboratories, Academic & Research Institutes and Contract Research Organizations, Other End Users), End User for Service (Pharmaceutical & Biotechnology Companies and Academic Institutions) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and restraints influencing the growth of the immunohistochemistry market. A detailed analysis of the key industry players has been done to provide insights into their business overview, service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the immunohistochemistry market. This report covers a competitive analysis of top players and upcoming startups in the immunohistochemistry market ecosystem.

The scope of the report covers detailed information regarding the primary factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the immunohistochemistry market. A thorough analysis of the key industry players has been conducted to provide insights into their business overview, solutions, and services; key strategies; new product & service launches, acquisitions, and recent developments associated with the immunohistochemistry market. This report covers the competitive analysis of upcoming startups in the immunohistochemistry market ecosystem.

Key Benefits of Buying the Report

This report provides a detailed picture of the immunohistochemistry market. It aims at estimating the size and future growth potential of the market across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

The report provides insights on the following pointers:

Analysis of key drivers (Rising Geriatric Population and Increasing Cancer Prevalence, Innovations and advancements in Immunohistochemistry (IHC) Technology, Reimbursement Coverage for Immunohistochemistry (IHC) Tests, Rising Adoption of Digital Pathology), restraint (Adoption of alternative technologies and a high degree of consolidation), opportunities (Rising demand for personalized medicine, Growing adoption of companion diagnostics, Growth opportunities in emerging countries, Integration of artificial intelligence in IHC), Challenges (Stringent regulatory requirements, Lack of Standardization)

• Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the Immunohistochemistry market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the Immunohistochemistry market across varied regions.
• Market Diversification: Exhaustive information about new, untapped geographies, recent developments, and investments in the Immunohistochemistry market

Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like F. Hoffman-La Roche Ltd (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US) among others in the Immunohistochemistry market. The report also helps stakeholders understand the pulse of the IHC market and provides them with information on key market drivers, restraints, challenges, and opportunities. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.

Table of Contents

1               INTRODUCTION              51

1.1           STUDY OBJECTIVES       51

1.2           MARKET DEFINITION   51

1.3           STUDY SCOPE   52

1.3.1        MARKET SEGMENTATION & REGIONAL SCOPE 52

1.3.2        INCLUSIONS & EXCLUSIONS       53

1.3.3        YEARS CONSIDERED      54

1.3.4        CURRENCY CONSIDERED            55

1.4           STAKEHOLDERS               55

1.5           SUMMARY OF CHANGES               55

2               RESEARCH METHODOLOGY       57

2.1           RESEARCH DATA              57

2.1.1        SECONDARY DATA          58

2.1.1.1    Key sources of secondary data            58

2.1.1.2    Key objectives of secondary research                 58

2.1.2        PRIMARY DATA 59

2.1.2.1    Breakdown of primaries      59

2.1.2.2    Key objectives of primary research    60

2.2           MARKET SIZE ESTIMATION         60

2.2.1        GLOBAL MARKET SIZE ESTIMATION      60

2.2.1.1    Revenue share analysis (bottom-up approach)                61

2.2.1.2    Secondary data      62

2.2.1.3    Primary interviews and MnM repository analysis           62

2.2.2        INSIGHTS FROM PRIMARY EXPERTS        63

2.2.3        SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)       63

2.3           MARKET GROWTH RATE PROJECTION  65

2.4           DATA TRIANGULATION                67

2.5           STUDY ASSUMPTIONS  68

2.6           RESEARCH LIMITATIONS             69

2.7           RISK ANALYSIS  69

3               EXECUTIVE SUMMARY  70

3.1           KEY INSIGHTS & MARKET HIGHLIGHTS 74

3.2           STRATEGIC IMPERATIVES FOR STAKEHOLDERS                 74

3.3           DISRUPTIVE TRENDS SHAPING IMMUNOHISTOCHEMISTRY MARKET     75

3.4           HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS                 75

3.5           GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST                 76

4               PREMIUM INSIGHTS       77

4.1           IMMUNOHISTOCHEMISTRY MARKET OVERVIEW                 77

4.2          NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION AND COUNTRY, 2024  78

4.3           IMMUNOHISTOCHEMISTRY PRODUCTS MARKET SHARE, BY END USER, 2024           78

4.4           IMMUNOHISTOCHEMISTRY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES         79

4.5           UNMET NEEDS & WHITE SPACES              79

4.6           INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES              80

4.7           EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS                 80

4.8           STRATEGIC MOVES BY TIER-1/2/3 PLAYERS        81

4.9           VC/PRIVATE EQUITY INVESTMENT TRENDS      81

4.10         SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES       82

5               MARKET OVERVIEW       83

5.1           INTRODUCTION              83

5.2           MARKET DYNAMICS       83

5.2.1        DRIVERS               84

5.2.1.1    Increasing adoption of companion diagnostics                84

5.2.1.2    Favorable reimbursement coverage for immunohistochemistry tests        85

5.2.1.3    Growing focus on digital pathology   86

5.2.2        RESTRAINTS      88

5.2.2.1    Adoption of alternative technologies in molecular diagnostics and research 88

5.2.2.2    Highly consolidated global market     88

5.2.3        OPPORTUNITIES              89

5.2.3.1    Rising demand for precision/personalized medicines    89

5.2.3.2    High growth opportunities in emerging economies        90

5.2.3.3    Integration of AI in immunohistochemistry     91

5.2.4        CHALLENGES    91

5.2.4.1    Stringent regulatory requirements for tissue diagnostic instruments and consumables            91

5.2.4.2    Lack of preanalytical and analytical method standardization                 91

5.3           TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS            92

5.4           PRICING ANALYSIS          93

5.4.1        AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS, BY KEY PLAYER, 2022–2024        93

5.4.2        AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS, BY REGION, 2022–2024                 95

5.5           TECHNOLOGY ANALYSIS             98

5.5.1        KEY TECHNOLOGIES     98

5.5.1.1    Automated immunohistochemistry systems    98

5.5.1.2    Multiplex immunohistochemistry      98

5.5.2        COMPLEMENTARY TECHNOLOGIES       99

5.5.2.1    Chromogenic detection       99

5.5.2.2    Fluorescent detection           99

5.5.3        ADJACENT TECHNOLOGIES       99

5.5.3.1    In situ hybridization             99

5.6           PATENT ANALYSIS          100

5.6.1        METHODOLOGY              100

5.6.2        NUMBER OF PATENTS FILED, BY DOCUMENT TYPE                 100

5.6.3        LIST OF KEY PATENTS   102

5.7           TRADE ANALYSIS             103

5.7.1        IMPORT DATA FOR HS CODE 3822.00, 2020–2024                 103

5.7.2        EXPORT DATA FOR HS CODE 3822.00, 2020–2024                 104

5.8           VALUE CHAIN ANALYSIS               104

5.9           ECOSYSTEM ANALYSIS  106

5.9.1        ROLE IN ECOSYSTEM     108

5.10         PORTER’S FIVE FORCES ANALYSIS           108

5.10.1      INTENSITY OF COMPETITIVE RIVALRY 110

5.10.2      BARGAINING POWER OF SUPPLIERS       110

5.10.3      BARGAINING POWER OF BUYERS             110

5.10.4      THREAT OF SUBSTITUTES          110

5.10.5      THREAT OF NEW ENTRANTS      110

5.11         KEY STAKEHOLDERS & BUYING CRITERIA            111

5.11.1      KEY STAKEHOLDERS IN BUYING PROCESS           111

5.11.2      KEY BUYING CRITERIA  112

5.12         TARIFF & REGULATORY ANALYSIS           114

5.12.1      TARIFF DATA ANALYSIS                114

5.12.2      REGULATORY LANDSCAPE         115

5.12.2.1  North America      115

5.12.2.1.1                US           115

5.12.2.1.2                Canada   117

5.12.2.2  Europe   117

5.12.2.3  Asia Pacific            119

5.12.2.3.1                Japan      119

5.12.2.3.2                China      120

5.12.2.3.3                India       120

5.12.2.4  Latin America       121

5.12.2.4.1                Brazil      121

5.12.3      REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS             122

5.13         KEY CONFERENCES & EVENTS, 2025–2026              125

5.14         INVESTMENT & FUNDING SCENARIO     126

5.15         IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET               127

5.16         IMPACT OF 2025 US TARIFF ON IMMUNOHISTOCHEMISTRY MARKET     130

5.16.1      KEY TARIFF RATES          130

5.16.2      PRICE IMPACT ANALYSIS             131

5.16.3      IMPACT ON KEY COUNTRIES/REGIONS 132

5.16.3.1  North America      132

5.16.3.1.1                US           132

5.16.3.2  Europe   132

5.16.3.3  Asia Pacific            132

5.16.3.4  Rest of the World 133

5.16.4      IMPACT ON END-USE INDUSTRIES          133

5.16.4.1  Pharmaceutical & biopharmaceutical companies            133

5.16.4.2  Hospitals & clinics                133

5.16.4.3  Academic & research institutes          133

5.16.4.4  Contract research organizations         134

6               IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING                 135

6.1           INTRODUCTION              136

6.2           ANTIBODIES      136

6.2.1        IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE     139

6.2.1.1    Primary antibodies               139

6.2.1.1.1 Increasing adoption of targeted immunotherapy and custom antibody development to drive segment           139

6.2.1.2    Secondary antibodies           142

6.2.1.2.1 Better signal amplification and easier manufacturing process to fuel segment growth             142

6.2.2        IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY        146

6.2.2.1    Monoclonal antibodies        149

6.2.2.1.1 Increased applications in cancer diagnostics to support segment growth    149

6.2.2.2    Polyclonal antibodies           152

6.2.2.2.1 Better sensitivity and higher resistance to changes in antigen conformation to augment segment growth       152

6.2.3        IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS      154

6.2.3.1    Class I/II assay antibodies  155

6.2.3.1.1 Focus on precision medicine and standardized reagents to favor segment growth    155

6.2.3.2    Class III assay antibodies    158

6.2.3.2.1 Expansion of targeted therapies to augment segment growth                 158

6.3           REAGENTS          161

6.3.1        BLOCKING SERA & REAGENTS   164

6.3.1.1    Need to prevent non-specific binding and provide accurate outcomes to drive adoption 164

6.3.2        CHROMOGENIC SUBSTRATES   167

6.3.2.1    Rapid detection and faster diagnosis to propel segment growth                 167

6.3.3        FIXATION REAGENTS    170

6.3.3.1    Increased focus on retaining tissue morphology and antigenicity of target molecules to support adoption            170

6.3.4        ORGANIC SOLVENTS     173

6.3.4.1    Need to prevent physical damage in specimens and improve clarity in tissue sample visualization to drive market      173

6.3.5        PROTEOLYTIC ENZYMES              175

6.3.5.1    Proteolytic enzymes to improve accessibility of target antibodies and DNA                175

6.3.6        DILUENTS           178

6.3.6.1    Need for reducing non-specific background staining during immunostaining to aid segment growth            178

6.3.7        OTHER REAGENTS          181

6.4           KITS       184

6.4.1        HUMAN IMMUNOHISTOCHEMISTRY KITS            187

6.4.1.1    Increasing focus on cancer research to fuel segment growth                 187

6.4.2        ANIMAL IMMUNOHISTOCHEMISTRY KITS            190

6.4.2.1    Rising focus on drug safety and efficacy in preclinical drug testing to boost segment growth     190

6.5           INSTRUMENTS & SOFTWARE     193

6.5.1        IHC STAINERS   196

6.5.1.1    Increased availability of automated IHC stainers to fuel segment growth    196

6.5.2        SAMPLE PREPARATION INSTRUMENTS 199

6.5.2.1    Tissue processors 202

6.5.2.1.1 Rising biopsy volumes and increasing workflow automation to fuel segment growth             202

6.5.2.2    Microtomes            204

6.5.2.2.1 High precision demand and increased workforce challenges to aid segment growth    204

6.5.2.3    Other sample preparation instruments             207

6.5.3        IMAGE ANALYSIS INSTRUMENTS              210

6.5.3.1    Escalating demand for objective and reproducible quantification of IHC-stained tissue to boost segment growth               210

6.6           SERVICES             213

6.6.1        INCREASED COMPLEXITY OF BIOMARKER REQUIREMENTS AND EXPANSION OF GLOBAL CLINICAL TRIALS TO AID MARKET GROWTH           213

7               IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION                 216

7.1           INTRODUCTION              217

7.2           DIAGNOSTIC APPLICATIONS     217

7.2.1        CANCER                220

7.2.1.1    Automation, AI-enhanced quantitation, and multiplexing to accelerate global cancer IHC adoption              220

7.2.2        INFECTIOUS DISEASES 223

7.2.2.1    Multiplex pathogen panels, automation, and AI-driven imaging to boost market growth        223

7.2.3        AUTOIMMUNE DISEASES             226

7.2.3.1    Focus on AI-powered multiplex imaging and automated analysis to propel market growth      226

7.2.4        NEPHROLOGICAL DISEASES      229

7.2.4.1    Better understanding of novel renal biomarkers and virtual multiplexing to accelerate market growth         229

7.2.5        NEUROLOGICAL DISEASES         232

7.2.5.1    Advances in neuroimmunopathology, novel biomarker discovery, multiplexing, and AI-supported image analysis to drive market   232

7.2.6        OTHER DIAGNOSTIC APPLICATIONS     235

7.3           RESEARCH APPLICATIONS          238

7.3.1        DRUG DEVELOPMENT & TESTING           241

7.3.1.1    AI-enabled quantitation, regulatory support, and organ-on-chip integration to propel growth in drug development          241

7.3.2        OTHER RESEARCH APPLICATIONS          244

7.4           FORENSIC APPLICATIONS           247

7.4.1        ADVANCEMENTS IN VALIDATED INJURY AND DEATH MARKERS WITH IHC INTEGRATION IN FORENSIC IMAGING TO DRIVE MARKET 247

8               IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER            250

8.1           INTRODUCTION              251

8.2           HOSPITALS & DIAGNOSTIC LABORATORIES       251

8.2.1        EXPANSION OF DIAGNOSTIC INFRASTRUCTURE AND DIGITAL AUTOMATION TO DRIVE GLOBAL MARKET GROWTH                 251

8.3           ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS             254

8.3.1        INNOVATION IN MULTIPLEX AND AI-ENABLED IMMUNOHISTOCHEMISTRY TO FUEL GLOBAL MARKET EXPANSION        254

8.4           OTHER END USERS         258

9               IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER     261

9.1           INTRODUCTION              262

9.2           PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES       262

9.2.1        INTEGRATION OF MULTIPLEX IHC SERVICES WITH REGULATORY-CLEARED WORKFLOWS TO AUGMENT MARKET GROWTH             262

9.3           ACADEMIC INSTITUTIONS          265

9.3.1        ADOPTION OF MULTIPLEX SPATIAL IMMUNOHISTOCHEMISTRY AND DIGITAL PATHOLOGY TO BOOST MARKET GROWTH           265

10            IMMUNOHISTOCHEMISTRY MARKET, BY REGION                 269

10.1         INTRODUCTION              270

10.2         NORTH AMERICA             270

10.2.1      MACROECONOMIC OUTLOOK FOR NORTH AMERICA                 277

10.2.2      US           278

10.2.2.1  US to dominate North American immunohistochemistry market during forecast period          278

10.2.3      CANADA               283

10.2.3.1  High incidence of cancer and increased demand for advanced diagnostics to propel market growth 283

10.3         EUROPE               288

10.3.1      MACROECONOMIC OUTLOOK FOR EUROPE      293

10.3.2      GERMANY           294

10.3.2.1  High investments in life science R&D and favorable reimbursement policies to drive market            294

10.3.3      UK          300

10.3.3.1  Rising prevalence of cancer and increasing government funding in healthcare research to augment market growth           300

10.3.4      FRANCE                305

10.3.4.1  Increased research in cancer diagnosis and treatment to support market growth       305

10.3.5      ITALY    310

10.3.5.1  Advanced healthcare infrastructure and high geriatric population to fuel market growth           310

10.3.6      SPAIN    315

10.3.6.1  Increased demand for personalized medicines to boost adoption of immunohistochemistry products   315

10.3.7      REST OF EUROPE             320

10.4         ASIA PACIFIC     325

10.4.1      MACROECONOMIC OUTLOOK FOR ASIA PACIFIC                 331

10.4.2      CHINA  333

10.4.2.1  Rising healthcare investments and increasing cancer burden to spur market growth              333

10.4.3      JAPAN   338

10.4.3.1  High geriatric population and increased government healthcare expenditure to support market growth              338

10.4.4      INDIA    343

10.4.4.1  Need for high-end pathology and diagnostic services to propel market growth       343

10.4.5      AUSTRALIA         348

10.4.5.1  Increased patient population and high demand for quality healthcare to aid market growth         348

10.4.6      SOUTH KOREA  353

10.4.6.1  Focus on precision healthcare and personalized medicines to drive market          353

10.4.7      REST OF ASIA PACIFIC   358

10.5         LATIN AMERICA                363

10.5.1      MACROECONOMIC OUTLOOK FOR LATIN AMERICA                 368

10.5.2      BRAZIL 369

10.5.2.1  Increasing incidence of chronic lifestyle diseases and rising investments by private companies to fuel market growth               369

10.5.3      MEXICO                374

10.5.3.1  Increasing research initiatives and rising cancer cases to drive market    374

10.5.4      REST OF LATIN AMERICA             379

10.6         MIDDLE EAST   384

10.6.1      MACROECONOMIC OUTLOOK FOR MIDDLE EAST                 389

10.6.2      GCC COUNTRIES              390

10.6.2.1  Kingdom of Saudi Arabia    395

10.6.2.1.1                Growing cancer burden and increasing focus on oncology-based research programs to augment market growth    395

10.6.2.2  UAE        400

10.6.2.2.1                Favorable government initiatives and high investments in healthcare infrastructure to fuel market growth          400

10.6.2.3  Rest of GCC Countries        405

10.6.3      REST OF MIDDLE EAST 410

10.7         AFRICA 415

10.7.1      RAPID RISE IN CANCER CASES AND HIGH HEALTHCARE INVESTMENTS TO DRIVE MARKET          415

10.7.2      MACROECONOMIC OUTLOOK FOR AFRICA        420

11            COMPETITIVE LANDSCAPE         422

11.1         INTRODUCTION              422

11.2         KEY PLAYER STRATEGIES/RIGHT TO WIN            422

11.2.1      OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET                422

11.3         REVENUE ANALYSIS, 2020–2024  424

11.4         MARKET SHARE ANALYSIS, 2024                 425

11.5         COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024                 427

11.5.1      STARS   427

11.5.2      EMERGING LEADERS     427

11.5.3      PERVASIVE PLAYERS      427

11.5.4      PARTICIPANTS 428

11.5.5      COMPANY FOOTPRINT: KEY PLAYERS, 2024         429

11.5.5.1  Company footprint               429

11.5.5.2  Region footprint   429

11.5.5.3  Offering footprint 430

11.5.5.4  Application footprint            431

11.6         COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024        432

11.6.1      PROGRESSIVE COMPANIES         432

11.6.2      RESPONSIVE COMPANIES            432

11.6.3      DYNAMIC COMPANIES  432

11.6.4      STARTING BLOCKS         432

11.6.5      COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024                 434

11.6.5.1  Detailed list of key startups/SMEs    434

11.6.5.2  Competitive benchmarking of key startups/SMEs          435

11.7         COMPANY VALUATION & FINANCIAL METRICS 436

11.7.1      FINANCIAL METRICS      436

11.7.2      COMPANY VALUATION 436

11.8         BRAND/PRODUCT COMPARISON             437

11.9         COMPETITIVE SCENARIO             438

11.9.1      PRODUCT APPROVALS 438

11.9.2      DEALS  439

11.9.3      EXPANSIONS     439

11.9.4      OTHER DEVELOPMENTS              440

12            COMPANY PROFILES      441

12.1         KEY PLAYERS     441

12.1.1      F. HOFFMANN-LA ROCHE LTD. 441

12.1.1.1  Business overview 441

12.1.1.2  Products/Services offered   442

12.1.1.3  Recent developments           446

12.1.1.3.1                Product launches and approvals         446

12.1.1.4  MnM view              448

12.1.1.4.1                Key strengths        448

12.1.1.4.2                Strategic choices   448

12.1.1.4.3                Weaknesses & competitive threats     449

12.1.2      DANAHER CORPORATION           450

12.1.2.1  Business overview 450

12.1.2.2  Products/Services offered   451

12.1.2.3  Recent developments           455

12.1.2.3.1                Product launches and approvals         455

12.1.2.3.2                Deals      456

12.1.2.4  MnM view              456

12.1.2.4.1                Key strengths        456

12.1.2.4.2                Strategic choices   456

12.1.2.4.3                Weaknesses & competitive threats     456

12.1.3      AGILENT TECHNOLOGIES, INC.                457

12.1.3.1  Business overview 457

12.1.3.2  Products/Services offered   458

12.1.3.3  Recent developments           462

12.1.3.3.1                Product approvals 462

12.1.3.3.2                Deals      463

12.1.3.3.3                Expansions             463

12.1.3.4  MnM view              464

12.1.3.4.1                Key strengths        464

12.1.3.4.2                Strategic choices   464

12.1.3.4.3                Weaknesses & competitive threats     464

12.1.4      PHC HOLDINGS CORPORATION               465

12.1.4.1  Business overview 465

12.1.4.2  Products/Services offered   466

12.1.4.3  Recent developments           471

12.1.4.3.1                Deals      471

12.1.4.4  MnM view              471

12.1.4.4.1                Key strengths        471

12.1.4.4.2                Strategic choices   472

12.1.4.4.3                Weaknesses & competitive threats     472

12.1.5      THERMO FISHER SCIENTIFIC INC.            473

12.1.5.1  Business overview 473

12.1.5.2  Products/Services offered   474

12.1.5.3  MnM view              478

12.1.5.3.1                Key strengths        478

12.1.5.3.2                Strategic choices   478

12.1.5.3.3                Weaknesses & competitive threats     478

12.1.6      MERCK KGAA    479

12.1.6.1  Business overview 479

12.1.6.2  Products/Services offered   480

12.1.7      BIO-RAD LABORATORIES, INC.  489

12.1.7.1  Business overview 489

12.1.7.2  Products/Services offered   490

12.1.8      BIO-TECHNE     494

12.1.8.1  Business overview 494

12.1.8.2  Products/Services offered   495

12.1.8.3  Recent developments           498

12.1.8.3.1                Deals      498

12.1.8.3.2                Other developments             499

12.1.9      BECTON, DICKINSON AND COMPANY (BD)         500

12.1.9.1  Business overview 500

12.1.9.2  Products/Services offered   501

12.1.10   TAKARA BIO INC.             507

12.1.10.1                 Business overview 507

12.1.10.2                 Products/Services offered   508

12.1.11   ENZO BIOCHEM INC.     514

12.1.11.1                 Business overview 514

12.1.11.2                 Products/Services offered   515

12.1.11.3                 Recent developments           517

12.1.11.3.1             Expansions             517

12.1.12   SINO BIOLOGICAL, INC.                518

12.1.12.1                 Business overview 518

12.1.12.2                 Products/Services offered   518

12.1.13   SAKURA FINETEK JAPAN CO., LTD.          520

12.1.13.1                 Business overview 520

12.1.13.2                 Products/Services offered   520

12.1.13.3                 Recent developments           523

12.1.13.3.1             Product launches  523

12.1.13.3.2             Deals      524

12.1.14   CELL SIGNALING TECHNOLOGY, INC.   525

12.1.14.1                 Business overview 525

12.1.14.2                 Products/Services offered   525

12.1.14.3                 Recent developments           529

12.1.14.3.1             Deals      529

12.1.15   BIO SB  530

12.1.15.1                 Business overview 530

12.1.15.2                 Products/Services offered   530

12.1.15.3                 Recent developments           535

12.1.15.3.1             Product launches  535

12.1.16   MILTENYI BIOTEC           536

12.1.16.1                 Business overview 536

12.1.16.2                 Products/Services offered   536

12.1.17   ORIGENE TECHNOLOGIES, INC.                539

12.1.17.1                 Business overview 539

12.1.17.2                 Products/Services offered   539

12.2         OTHER PLAYERS              544

12.2.1      EAGLEBIO           544

12.2.2      BIOCARE MEDICAL, LLC                545

12.2.3      ELABSCIENCE   546

12.2.4      BIOGENEX          548

12.2.5      DIAGNOSTIC BIOSYSTEMS INC. 549

12.2.6      HISTO-LINE LABORATORIES      551

12.2.7      ROCKLAND IMMUNOCHEMICALS, INC. 553

12.2.8      CANDOR BIOSCIENCE GMBH     554

12.2.9      GENEMED BIOTECHNOLOGIES, INC.      555

13            APPENDIX           556

13.1         DISCUSSION GUIDE        556

13.2         KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL                560

13.3         CUSTOMIZATION OPTIONS        562

13.4         RELATED REPORTS         562

13.5         AUTHOR DETAILS           563

LIST OF TABLES

TABLE 1                IMMUNOHISTOCHEMISTRY MARKET: INCLUSIONS & EXCLUSIONS       53

TABLE 2                IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS  66

TABLE 3                IMMUNOHISTOCHEMISTRY MARKET: RISK ANALYSIS            69

TABLE 4                IMMUNOHISTOCHEMISTRY MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS           84

TABLE 5                CPT CODES FOR IMMUNOHISTOCHEMISTRY PROCEDURES    85

TABLE 6                AVERAGE SELLING PRICE TREND OF IMMUNOHISTOCHEMISTRY PRODUCTS,

BY KEY PLAYER, 2022–2024 (USD MILLION)           93

TABLE 7                AVERAGE SELLING PRICE TREND OF INSTRUMENTS, BY REGION,

2022–2024 (USD MILLION)            95

TABLE 8                AVERAGE SELLING PRICE TREND OF KITS, BY REGION, 2022–2024 (USD MILLION)          96

TABLE 9                AVERAGE SELLING PRICE TREND OF ANTIBODIES, BY REGION,

2022–2024 (USD MILLION)            96

TABLE 10              NUMBER OF PATENTS FILED, BY DOCUMENT TYPE, 2014–2024                 100

TABLE 11              LIST OF KEY PATENTS IN IMMUNOHISTOCHEMISTRY MARKET, 2023–2025                102

TABLE 12              IMPORT DATA FOR HS CODE 3822.00, BY COUNTRY,

2020–2024 (USD THOUSAND)      103

TABLE 13              EXPORT DATA FOR HS CODE 3822.00, BY COUNTRY,

2020–2024 (USD THOUSAND)      104

TABLE 14              IMMUNOHISTOCHEMISTRY MARKET: ROLE IN ECOSYSTEM       108

TABLE 15              IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES 109

TABLE 16              INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING              111

TABLE 17              KEY BUYING CRITERIA FOR MAJOR END USERS                 112

TABLE 18              IMMUNOHISTOCHEMISTRY MARKET: TARIFF DATA FOR HS CODES 9027.50, 3822.00, AND 3507                 114

TABLE 19              US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES              115

TABLE 20              EUROPE: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES  117

TABLE 21              JAPAN: CLASSIFICATION OF IN VITRO DIAGNOSTIC REAGENTS              119

TABLE 22              JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS             120

TABLE 23              CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS             120

TABLE 24              NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 122

TABLE 25              EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS           123

TABLE 26              ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 123

TABLE 27              REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS                 124

TABLE 28              LIST OF KEY CONFERENCES & EVENTS IN IMMUNOHISTOCHEMISTRY MARKET, JANUARY 2025–DECEMBER 2026                125

TABLE 29              INVESTMENT & FUNDING SCENARIO OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET, 2022−2025                 126

TABLE 30              KEY PLAYERS IMPLEMENTING AI/GEN AI IN IMMUNOCHEMISTRY MARKET  129

TABLE 31              US-ADJUSTED RECIPROCAL TARIFF RATES                 130

TABLE 32              KEY PRODUCT-RELATED TARIFF: LIVE ANIMALS, PRODUCTS OF ANIMAL ORIGIN, AND MISCELLANEOUS CHEMICAL PRODUCTS             131

TABLE 33              CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES            132

TABLE 34              IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION)     136

TABLE 35              IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            137

TABLE 36              NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 137

TABLE 37              EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            137

TABLE 38              ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 138

TABLE 39              LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 138

TABLE 40              MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)                 138

TABLE 41              GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 139

TABLE 42              IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            139

TABLE 43              PRIMARY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)            140

TABLE 44              NORTH AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            140

TABLE 45              EUROPE: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 46              ASIA PACIFIC: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 47              LATIN AMERICA: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            141

TABLE 48              MIDDLE EAST: PRIMARY ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            142

TABLE 49              GCC COUNTRIES: PRIMARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            142

TABLE 50              SECONDARY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)            143

TABLE 51              NORTH AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            143

TABLE 52              EUROPE: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            144

TABLE 53              ASIA PACIFIC: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            144

TABLE 54              LATIN AMERICA: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            145

TABLE 55              MIDDLE EAST: SECONDARY ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            145

TABLE 56              GCC COUNTRIES: SECONDARY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            145

TABLE 57              IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            146

TABLE 58              IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            146

TABLE 59              NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 146

TABLE 60              EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            147

TABLE 61              ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 147

TABLE 62              LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 148

TABLE 63              MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)                 148

TABLE 64              GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 148

TABLE 65              MONOCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)          149

TABLE 66              NORTH AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 67              EUROPE: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 68              ASIA PACIFIC: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            150

TABLE 69              LATIN AMERICA: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 70              MIDDLE EAST: MONOCLONAL ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            151

TABLE 71              GCC COUNTRIES: MONOCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            151

TABLE 72              POLYCLONAL ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)          152

TABLE 73              NORTH AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            152

TABLE 74              EUROPE: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 75              ASIA PACIFIC: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 76              LATIN AMERICA: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            153

TABLE 77              MIDDLE EAST: POLYCLONAL ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            154

TABLE 78              GCC COUNTRIES: POLYCLONAL ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            154

TABLE 79              IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS,

2023–2030 (USD MILLION)            154

TABLE 80              CLASS I/II ASSAY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)          155

TABLE 81              NORTH AMERICA: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 82              EUROPE: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            156

TABLE 83              ASIA PACIFIC: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 84              LATIN AMERICA: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            157

TABLE 85              MIDDLE EAST: CLASS I/II ASSAY ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            157

TABLE 86              GCC COUNTRIES: CLASS I/II ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            158

TABLE 87              CLASS III ASSAY ANTIBODIES MARKET, BY REGION, 2023–2030 (USD MILLION)          159

TABLE 88              NORTH AMERICA: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            159

TABLE 89              EUROPE: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            159

TABLE 90              ASIA PACIFIC: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            160

TABLE 91              LATIN AMERICA: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            160

TABLE 92              MIDDLE EAST: CLASS III ASSAY ANTIBODIES MARKET, BY REGION,

2023–2030 (USD MILLION)            160

TABLE 93              GCC COUNTRIES: CLASS III ASSAY ANTIBODIES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            161

TABLE 94              IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            161

TABLE 95              IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            162

TABLE 96              NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 162

TABLE 97              EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            162

TABLE 98              ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 163

TABLE 99              LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 163

TABLE 100            MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            163

TABLE 101            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 164

TABLE 102            BLOCKING SERA & REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)          164

TABLE 103            NORTH AMERICA: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 104            EUROPE: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 105            ASIA PACIFIC: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            165

TABLE 106            LATIN AMERICA: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 107            MIDDLE EAST: BLOCKING SERA & REAGENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            166

TABLE 108            GCC COUNTRIES: BLOCKING SERA & REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            166

TABLE 109            CHROMOGENIC SUBSTRATES MARKET, BY REGION, 2023–2030 (USD MILLION)          167

TABLE 110            NORTH AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            168

TABLE 111            EUROPE: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            168

TABLE 112            ASIA PACIFIC: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            168

TABLE 113            LATIN AMERICA: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            169

TABLE 114            MIDDLE EAST: CHROMOGENIC SUBSTRATES MARKET, BY REGION,

2023–2030 (USD MILLION)            169

TABLE 115            GCC COUNTRIES: CHROMOGENIC SUBSTRATES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            169

TABLE 116            FIXATION REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)            170

TABLE 117            NORTH AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            171

TABLE 118            EUROPE: FIXATION REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     171

TABLE 119            ASIA PACIFIC: FIXATION REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            171

TABLE 120          LATIN AMERICA: FIXATION REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            172

TABLE 121            MIDDLE EAST: FIXATION REAGENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            172

TABLE 122            GCC COUNTRIES: FIXATION REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            172

TABLE 123            ORGANIC SOLVENTS MARKET, BY REGION, 2023–2030 (USD MILLION)            173

TABLE 124            NORTH AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            173

TABLE 125            EUROPE: ORGANIC SOLVENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     174

TABLE 126            ASIA PACIFIC: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            174

TABLE 127            LATIN AMERICA: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            174

TABLE 128            MIDDLE EAST: ORGANIC SOLVENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            175

TABLE 129            GCC COUNTRIES: ORGANIC SOLVENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            175

TABLE 130            PROTEOLYTIC ENZYMES MARKET, BY REGION, 2023–2030 (USD MILLION)            176

TABLE 131            NORTH AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            176

TABLE 132            EUROPE: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            176

TABLE 133            ASIA PACIFIC: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            177

TABLE 134            LATIN AMERICA: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            177

TABLE 135            MIDDLE EAST: PROTEOLYTIC ENZYMES MARKET, BY REGION,

2023–2030 (USD MILLION)            177

TABLE 136            GCC COUNTRIES: PROTEOLYTIC ENZYMES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            178

TABLE 137            DILUENTS MARKET, BY REGION, 2023–2030 (USD MILLION)            178

TABLE 138            NORTH AMERICA: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     179

TABLE 139            EUROPE: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            179

TABLE 140            ASIA PACIFIC: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     179

TABLE 141            LATIN AMERICA: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     180

TABLE 142            MIDDLE EAST: DILUENTS MARKET, BY REGION, 2023–2030 (USD MILLION)            180

TABLE 143            GCC COUNTRIES: DILUENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     180

TABLE 144            OTHER REAGENTS MARKET, BY REGION, 2023–2030 (USD MILLION)       181

TABLE 145            NORTH AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            182

TABLE 146            EUROPE: OTHER REAGENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     182

TABLE 147            ASIA PACIFIC: OTHER REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            182

TABLE 148            LATIN AMERICA: OTHER REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            183

TABLE 149            MIDDLE EAST: OTHER REAGENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            183

TABLE 150            GCC COUNTRIES: OTHER REAGENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            183

TABLE 151            IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION)                184

TABLE 152            IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)          184

TABLE 153            NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            185

TABLE 154            EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            185

TABLE 155            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            185

TABLE 156            LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            186

TABLE 157            MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,

2023–2030 (USD MILLION)            186

TABLE 158            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            186

TABLE 159            HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,

2023–2030 (USD MILLION)            187

TABLE 160            NORTH AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       187

TABLE 161            EUROPE: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            188

TABLE 162            ASIA PACIFIC: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       188

TABLE 163            LATIN AMERICA: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       189

TABLE 164            MIDDLE EAST: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)       189

TABLE 165            GCC COUNTRIES: HUMAN IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       189

TABLE 166            ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION,

2023–2030 (USD MILLION)            190

TABLE 167            NORTH AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       190

TABLE 168            EUROPE: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            191

TABLE 169            ASIA PACIFIC: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       191

TABLE 170            LATIN AMERICA: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       192

TABLE 171            MIDDLE EAST: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY REGION, 2023–2030 (USD MILLION)       192

TABLE 172            GCC COUNTRIES: ANIMAL IMMUNOHISTOCHEMISTRY KITS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)       192

TABLE 173            IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE,

2023–2030 (USD MILLION)            193

TABLE 174            IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)                 193

TABLE 175            NORTH AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194

TABLE 176            EUROPE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               194

TABLE 177            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 194

TABLE 178            LATIN AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 195

TABLE 179            MIDDLE EAST: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION) 195

TABLE 180            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 195

TABLE 181            IHC STAINERS MARKET, BY VOLUME, 2023–2030 (UNITS)                196

TABLE 182            IHC STAINERS MARKET, BY REGION, 2023–2030 (USD MILLION) 196

TABLE 183            NORTH AMERICA: IHC STAINERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            197

TABLE 184            EUROPE: IHC STAINERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            197

TABLE 185            ASIA PACIFIC: IHC STAINERS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     197

TABLE 186            LATIN AMERICA: IHC STAINERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            198

TABLE 187            MIDDLE EAST: IHC STAINERS MARKET, BY REGION, 2023–2030 (USD MILLION)          198

TABLE 188            GCC COUNTRIES: IHC STAINERS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            198

TABLE 189            SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            199

TABLE 190            SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            199

TABLE 191            NORTH AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            200

TABLE 192            EUROPE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            200

TABLE 193            ASIA PACIFIC: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            200

TABLE 194            LATIN AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            201

TABLE 195            MIDDLE EAST: SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            201

TABLE 196            GCC COUNTRIES: SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            201

TABLE 197            TISSUE PROCESSORS MARKET, BY REGION, 2023–2030 (USD MILLION)            202

TABLE 198            NORTH AMERICA: TISSUE PROCESSORS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            202

TABLE 199            EUROPE: TISSUE PROCESSORS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            203

TABLE 200            ASIA PACIFIC: TISSUE PROCESSORS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            203

TABLE 201            LATIN AMERICA: TISSUE PROCESSORS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            203

TABLE 202            MIDDLE EAST: TISSUE PROCESSORS MARKET, BY REGION,

2023–2030 (USD MILLION)            204

TABLE 203            GCC COUNTRIES: TISSUE PROCESSORS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            204

TABLE 204            MICROTOMES MARKET, BY REGION, 2023–2030 (USD MILLION) 205

TABLE 205            NORTH AMERICA: MICROTOMES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            205

TABLE 206            EUROPE: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            205

TABLE 207            ASIA PACIFIC: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     206

TABLE 208            LATIN AMERICA: MICROTOMES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)     206

TABLE 209            MIDDLE EAST: MICROTOMES MARKET, BY REGION, 2023–2030 (USD MILLION)          206

TABLE 210            GCC COUNTRIES: MICROTOMES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            207

TABLE 211            OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            207

TABLE 212            NORTH AMERICA: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               208

TABLE 213            EUROPE: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)            208

TABLE 214            ASIA PACIFIC: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               208

TABLE 215            LATIN AMERICA: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 216            MIDDLE EAST: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION)                 209

TABLE 217            GCC COUNTRIES: OTHER SAMPLE PREPARATION INSTRUMENTS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               209

TABLE 218            IMAGE ANALYSIS INSTRUMENTS MARKET, BY REGION, 2023–2030 (USD MILLION)          210

TABLE 219            NORTH AMERICA: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            211

TABLE 220            EUROPE: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            211

TABLE 221            ASIA PACIFIC: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            211

TABLE 222            LATIN AMERICA: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            212

TABLE 223            MIDDLE EAST: IMAGE ANALYSIS INSTRUMENTS MARKET, BY REGION,

2023–2030 (USD MILLION)            212

TABLE 224            GCC COUNTRIES: IMAGE ANALYSIS INSTRUMENTS MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            212

TABLE 225            IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            213

TABLE 226            NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 214

TABLE 227            EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            214

TABLE 228            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            214

TABLE 229            LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 215

TABLE 230            MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY REGION,

2023–2030 (USD MILLION)            215

TABLE 231            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION)                 215

TABLE 232            IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)              217

TABLE 233            IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE,

2023–2030 (USD MILLION)            217

TABLE 234            IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)                 218

TABLE 235            NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 218

TABLE 236            EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               218

TABLE 237            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               219

TABLE 238            LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 219

TABLE 239            MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY REGION, 2023–2030 (USD MILLION)   219

TABLE 240            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 220

TABLE 241            IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER,

BY REGION, 2023–2030 (USD MILLION)   220

TABLE 242            NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)     221

TABLE 243            EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)     221

TABLE 244            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)     221

TABLE 245            LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)     222

TABLE 246            MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY REGION, 2023–2030 (USD MILLION)          222

TABLE 247            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR CANCER, BY COUNTRY, 2023–2030 (USD MILLION)     222

TABLE 248            IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)          223

TABLE 249            NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         223

TABLE 250            EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         224

TABLE 251            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         224

TABLE 252            LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         225

TABLE 253            MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2030 (USD MILLION)              225

TABLE 254            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         225

TABLE 255            IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION)          226

TABLE 256            NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         226

TABLE 257            EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         227

TABLE 258            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         227

TABLE 259            LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         228

TABLE 260            MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2023–2030 (USD MILLION)              228

TABLE 261            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         228

TABLE 262            IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)          229

TABLE 263            NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         229

TABLE 264            EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         230

TABLE 265            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         230

TABLE 266            LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         231

TABLE 267            MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)              231

TABLE 268            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEPHROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         231

TABLE 269            IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)          232

TABLE 270            NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         232

TABLE 271            EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         233

TABLE 272            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         233

TABLE 273            LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         234

TABLE 274            MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2023–2030 (USD MILLION)              234

TABLE 275            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2023–2030 (USD MILLION)         234

TABLE 276            OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY REGION, 2023–2030 (USD MILLION)   235

TABLE 277            NORTH AMERICA: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           235

TABLE 278            EUROPE: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 236

TABLE 279            ASIA PACIFIC: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           236

TABLE 280            LATIN AMERICA: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           237

TABLE 281            MIDDLE EAST: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)                237

TABLE 282            GCC COUNTRIES: OTHER IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           237

TABLE 283            IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE,

2023–2030 (USD MILLION)            238

TABLE 284            IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)                 238

TABLE 285            NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 239

TABLE 286            EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               239

TABLE 287            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               239

TABLE 288            LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 240

TABLE 289            MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY REGION, 2023–2030 (USD MILLION)   240

TABLE 290            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 240

TABLE 291            IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2023–2030 (USD MILLION)   241

TABLE 292            NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)      241

TABLE 293            EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)      242

TABLE 294            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)      242

TABLE 295            LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)      243

TABLE 296            MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY REGION, 2023–2030 (USD MILLION)           243

TABLE 297            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET FOR DRUG DEVELOPMENT & TESTING, BY COUNTRY, 2023–2030 (USD MILLION)      243

TABLE 298            OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY REGION, 2023–2030 (USD MILLION)   244

TABLE 299            NORTH AMERICA: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           244

TABLE 300            EUROPE: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 245

TABLE 301            ASIA PACIFIC: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           245

TABLE 302            LATIN AMERICA: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           246

TABLE 303            MIDDLE EAST: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY REGION, 2023–2030 (USD MILLION)                246

TABLE 304            GCC COUNTRIES: OTHER IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)           246

TABLE 305            IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY REGION,

2023–2030 (USD MILLION)            247

TABLE 306            NORTH AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 247

TABLE 307            EUROPE: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               248

TABLE 308            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               248

TABLE 309            LATIN AMERICA: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY COUNTRY, 2023–2030 (USD MILLION)               249

TABLE 310            MIDDLE EAST: IIMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET,

BY REGION, 2023–2030 (USD MILLION)   249

TABLE 311            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY FORENSIC APPLICATIONS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 249

TABLE 312            IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            251

TABLE 313            IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION)          252

TABLE 314            NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)                 252

TABLE 315            EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)                 252

TABLE 316            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)                 253

TABLE 317            LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)                 253

TABLE 318            MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2023–2030 (USD MILLION) 253

TABLE 319            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR HOSPITALS & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2023–2030 (USD MILLION)                 254

TABLE 320            IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION,

2023–2030 (USD MILLION)            255

TABLE 321            NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            255

TABLE 322            EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            256

TABLE 323            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            256

TABLE 324            LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            257

TABLE 325            MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY REGION,

2023–2030 (USD MILLION)            257

TABLE 326            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR ACADEMIC INSTITUTIONS AND CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY,

2023–2030 (USD MILLION)            257

TABLE 327            IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS,

BY REGION, 2023–2030 (USD MILLION)   258

TABLE 328            NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)            258

TABLE 329            EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD MILLION)            259

TABLE 330            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER

END USERS, BY COUNTRY, 2023–2030 (USD MILLION)     259

TABLE 331            LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER

END USERS, BY COUNTRY, 2023–2030 (USD MILLION)     260

TABLE 332            MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER

END USERS, BY REGION, 2023–2030 (USD MILLION)          260

TABLE 333            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET FOR OTHER

END USERS, BY COUNTRY, 2023–2030 (USD MILLION)     260

TABLE 334            IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            262

TABLE 335            IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2023–2030 (USD MILLION)   263

TABLE 336            NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,

2023–2030 (USD MILLION)            263

TABLE 337            EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION)   263

TABLE 338            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,

2023–2030 (USD MILLION)            264

TABLE 339            LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,

2023–2030 (USD MILLION)            264

TABLE 340            MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION,

2023–2030 (USD MILLION)            264

TABLE 341            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY,

2023–2030 (USD MILLION)            265

TABLE 342            IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS,

BY REGION, 2023–2030 (USD MILLION)   266

TABLE 343            NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION)     266

TABLE 344            EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION)       266

TABLE 345            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION)     267

TABLE 346            LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION)     267

TABLE 347            MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY REGION, 2023–2030 (USD MILLION)            267

TABLE 348            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET FOR ACADEMIC INSTITUTIONS, BY COUNTRY, 2023–2030 (USD MILLION)     268

TABLE 349            IMMUNOHISTOCHEMISTRY MARKET, BY REGION, 2023–2030 (USD MILLION)          270

TABLE 350            NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            272

TABLE 351            NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            272

TABLE 352            NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 272

TABLE 353            NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           273

TABLE 354            NORTH AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         273

TABLE 355            NORTH AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            273

TABLE 356            NORTH AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 274

TABLE 357            NORTH AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 274

TABLE 358            NORTH AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            275

TABLE 359            NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            275

TABLE 360            NORTH AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            275

TABLE 361            NORTH AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            276

TABLE 362            NORTH AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)                 276

TABLE 363            NORTH AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 276

TABLE 364            NORTH AMERICA: KEY MACROINDICATORS                 277

TABLE 365            US: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET     278

TABLE 366            US: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            279

TABLE 367            US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            279

TABLE 368            US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            280

TABLE 369            US: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)                 280

TABLE 370            US: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                 280

TABLE 371            US: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            281

TABLE 372            US: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            281

TABLE 373            US: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            281

TABLE 374            US: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            282

TABLE 375            US: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 282

TABLE 376            US: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 282

TABLE 377            US: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            283

TABLE 378            US: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            283

TABLE 379            CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            284

TABLE 380            CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            284

TABLE 381            CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            284

TABLE 382            CANADA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            285

TABLE 383            CANADA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY TYPE, 2023–2030 (USD MILLION)         285

TABLE 384            CANADA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            285

TABLE 385            CANADA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            286

TABLE 386            CANADA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            286

TABLE 387            CANADA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            286

TABLE 388            CANADA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         287

TABLE 389            CANADA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         287

TABLE 390            CANADA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            287

TABLE 391            CANADA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            288

TABLE 392            EUROPE: RECENT DEVELOPMENTS IN IMMUNOHISTOCHEMISTRY MARKET     288

TABLE 393            EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            289

TABLE 394            EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            289

TABLE 395            EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            289

TABLE 396            EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            290

TABLE 397            EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            290

TABLE 398            EUROPE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY TYPE, 2023–2030 (USD MILLION)         290

TABLE 399            EUROPE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 400            EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 401            EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            291

TABLE 402            EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            292

TABLE 403            EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         292

TABLE 404            EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            292

TABLE 405            EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            293

TABLE 406            EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            293

TABLE 407            EUROPE: KEY MACROINDICATORS          294

TABLE 408            GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            295

TABLE 409            GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            295

TABLE 410            GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           296

TABLE 411            GERMANY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         296

TABLE 412            GERMANY: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY TYPE, 2023–2030 (USD MILLION)         296

TABLE 413            GERMANY: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            297

TABLE 414            GERMANY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            297

TABLE 415            GERMANY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            298

TABLE 416            GERMANY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            298

TABLE 417            GERMANY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         298

TABLE 418            GERMANY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         299

TABLE 419            GERMANY: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            299

TABLE 420            GERMANY: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            299

TABLE 421            UK: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            300

TABLE 422            UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            301

TABLE 423            UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            301

TABLE 424            UK: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)                 301

TABLE 425            UK: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)                 302

TABLE 426            UK: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            302

TABLE 427            UK: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            302

TABLE 428            UK: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            303

TABLE 429            UK: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            303

TABLE 430            UK: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 303

TABLE 431            UK: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 304

TABLE 432            UK: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            304

TABLE 433            UK: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            304

TABLE 434            FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            305

TABLE 435            FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            306

TABLE 436            FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            306

TABLE 437            FRANCE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            306

TABLE 438            FRANCE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY TYPE, 2023–2030 (USD MILLION)         307

TABLE 439            FRANCE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            307

TABLE 440            FRANCE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            308

TABLE 441            FRANCE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            308

TABLE 442            FRANCE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            308

TABLE 443            FRANCE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         309

TABLE 444            FRANCE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            309

TABLE 445            FRANCE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            309

TABLE 446            FRANCE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            310

TABLE 447            ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            310

TABLE 448            ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            311

TABLE 449            ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            311

TABLE 450            ITALY: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            311

TABLE 451            ITALY: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            312

TABLE 452            ITALY: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            312

TABLE 453            ITALY: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            313

TABLE 454            ITALY: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            313

TABLE 455            ITALY: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            313

TABLE 456            ITALY: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            314

TABLE 457            ITALY: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 314

TABLE 458            ITALY: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            314

TABLE 459            ITALY: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            315

TABLE 460            SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            315

TABLE 461            SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            316

TABLE 462            SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            316

TABLE 463            SPAIN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            316

TABLE 464            SPAIN: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            317

TABLE 465            SPAIN: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            317

TABLE 466            SPAIN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            318

TABLE 467            SPAIN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            318

TABLE 468            SPAIN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            318

TABLE 469            SPAIN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            319

TABLE 470            SPAIN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 319

TABLE 471            SPAIN: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            319

TABLE 472            SPAIN: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            320

TABLE 473            REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            320

TABLE 474            REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         321

TABLE 475            REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           321

TABLE 476            REST OF EUROPE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         321

TABLE 477            REST OF EUROPE: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            322

TABLE 478            REST OF EUROPE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 322

TABLE 479            REST OF EUROPE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 323

TABLE 480            REST OF EUROPE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            323

TABLE 481            REST OF EUROPE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            323

TABLE 482            REST OF EUROPE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            324

TABLE 483            REST OF EUROPE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            324

TABLE 484            REST OF EUROPE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)                 324

TABLE 485            REST OF EUROPE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 325

TABLE 486            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            327

TABLE 487            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            327

TABLE 488            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            327

TABLE 489            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           328

TABLE 490            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         328

TABLE 491            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            328

TABLE 492            ASIA PACIFIC: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            329

TABLE 493            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            329

TABLE 494            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            329

TABLE 495            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            330

TABLE 496            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         330

TABLE 497            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         330

TABLE 498            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)                 331

TABLE 499            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 331

TABLE 500            ASIA PACIFIC: KEY MACROINDICATORS                 332

TABLE 501            CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            333

TABLE 502            CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            334

TABLE 503            CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            334

TABLE 504            CHINA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            334

TABLE 505            CHINA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            335

TABLE 506            CHINA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            335

TABLE 507            CHINA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            336

TABLE 508            CHINA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            336

TABLE 509            CHINA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            336

TABLE 510            CHINA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            337

TABLE 511            CHINA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 337

TABLE 512            CHINA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            337

TABLE 513            CHINA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            338

TABLE 514            JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            339

TABLE 515            JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            339

TABLE 516            JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            339

TABLE 517            JAPAN: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            340

TABLE 518            JAPAN: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            340

TABLE 519            JAPAN: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            340

TABLE 520            JAPAN: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            341

TABLE 521            JAPAN: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            341

TABLE 522            JAPAN: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            341

TABLE 523            JAPAN: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            342

TABLE 524            JAPAN: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 342

TABLE 525            JAPAN: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            342

TABLE 526            JAPAN: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            343

TABLE 527            INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            344

TABLE 528            INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            344

TABLE 529            INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            344

TABLE 530            INDIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            345

TABLE 531            INDIA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            345

TABLE 532            INDIA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            345

TABLE 533            INDIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            346

TABLE 534            INDIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            346

TABLE 535            INDIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            346

TABLE 536            INDIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            347

TABLE 537            INDIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 347

TABLE 538            INDIA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            347

TABLE 539            INDIA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            348

TABLE 540            AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            349

TABLE 541            AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            349

TABLE 542            AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION)            349

TABLE 543            AUSTRALIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         350

TABLE 544            AUSTRALIA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY TYPE, 2023–2030 (USD MILLION)         350

TABLE 545            AUSTRALIA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            350

TABLE 546            AUSTRALIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            351

TABLE 547            AUSTRALIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            351

TABLE 548            AUSTRALIA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            351

TABLE 549            AUSTRALIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         352

TABLE 550            AUSTRALIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         352

TABLE 551            AUSTRALIA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            352

TABLE 552            AUSTRALIA: IMMUNOHISTOCHEMISTRY SEERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 353

TABLE 553            SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            354

TABLE 554            SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            354

TABLE 555            SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY, 2023–2030 (USD MILLION)            354

TABLE 556            SOUTH KOREA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         355

TABLE 557            SOUTH KOREA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            355

TABLE 558            SOUTH KOREA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            355

TABLE 559            SOUTH KOREA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            356

TABLE 560            SOUTH KOREA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            356

TABLE 561            SOUTH KOREA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            356

TABLE 562            SOUTH KOREA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            357

TABLE 563            SOUTH KOREA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         357

TABLE 564            SOUTH KOREA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)                 357

TABLE 565            SOUTH KOREA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 358

TABLE 566            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            358

TABLE 567            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         359

TABLE 568            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           359

TABLE 569            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         359

TABLE 570            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)     360

TABLE 571            REST OF ASIA PACIFIC: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 360

TABLE 572            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)            361

TABLE 573            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            361

TABLE 574            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)       361

TABLE 575            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     362

TABLE 576            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     362

TABLE 577            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET,

BY END USER, 2023–2030 (USD MILLION)               362

TABLE 578            REST OF ASIA PACIFIC: IMMUNOHISTOCHEMISTRY SERVICES MARKET,

BY END USER, 2023–2030 (USD MILLION)               363

TABLE 579            LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            363

TABLE 580            LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            364

TABLE 581            LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         364

TABLE 582            LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           364

TABLE 583            LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         365

TABLE 584            LATIN AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)            365

TABLE 585            LATIN AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            365

TABLE 586            LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            366

TABLE 587            LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            366

TABLE 588            LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            366

TABLE 589            LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            367

TABLE 590            LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            367

TABLE 591            LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)                 367

TABLE 592            LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 368

TABLE 593            LATIN AMERICA: KEY MACROINDICATORS                 369

TABLE 594            BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            370

TABLE 595            BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            370

TABLE 596            BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            370

TABLE 597            BRAZIL: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            371

TABLE 598            BRAZIL: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY TYPE, 2023–2030 (USD MILLION)         371

TABLE 599            BRAZIL: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            371

TABLE 600            BRAZIL: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            372

TABLE 601            BRAZIL: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            372

TABLE 602            BRAZIL: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            372

TABLE 603            BRAZIL: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            373

TABLE 604            BRAZIL: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 373

TABLE 605            BRAZIL: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            373

TABLE 606            BRAZIL: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            374

TABLE 607            MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            374

TABLE 608            MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            375

TABLE 609            MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            375

TABLE 610            MEXICO: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         375

TABLE 611            MEXICO: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET,

BY TYPE, 2023–2030 (USD MILLION)         376

TABLE 612            MEXICO: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            376

TABLE 613            MEXICO: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            377

TABLE 614            MEXICO: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            377

TABLE 615            MEXICO: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            377

TABLE 616            MEXICO: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         378

TABLE 617            MEXICO: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         378

TABLE 618            MEXICO: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            378

TABLE 619            MEXICO: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            379

TABLE 620            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 379

TABLE 621            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         380

TABLE 622            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           380

TABLE 623            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         380

TABLE 624            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY INSTRUMENTS & SOFTWARE MARKET, BY TYPE, 2023–2030 (USD MILLION)     381

TABLE 625            REST OF LATIN AMERICA: SAMPLE PREPARATION INSTRUMENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         381

TABLE 626            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         382

TABLE 627            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 382

TABLE 628            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)       382

TABLE 629            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     383

TABLE 630            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     383

TABLE 631            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET,

BY END USER, 2023–2030 (USD MILLION)               383

TABLE 632            REST OF LATIN AMERICA: IMMUNOHISTOCHEMISTRY SERVICES MARKET,

BY END USER, 2023–2030 (USD MILLION)               384

TABLE 633            MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY REGION,

2023–2030 (USD MILLION)            384

TABLE 634            MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            385

TABLE 635            MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            385

TABLE 636            MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           385

TABLE 637            MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         386

TABLE 638            MIDDLE EAST: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         386

TABLE 639            MIDDLE EAST: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            386

TABLE 640            MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            387

TABLE 641            MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            387

TABLE 642            MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            387

TABLE 643            MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         388

TABLE 644            MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         388

TABLE 645            MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)                 388

TABLE 646            MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 389

TABLE 647            MIDDLE EAST: KEY MACROINDICATORS                 390

TABLE 648            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY COUNTRY,

2023–2030 (USD MILLION)            390

TABLE 649            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            391

TABLE 650            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         391

TABLE 651            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           391

TABLE 652            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         392

TABLE 653            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            392

TABLE 654            GCC COUNTRIES: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            392

TABLE 655            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            393

TABLE 656            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            393

TABLE 657            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            393

TABLE 658            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            394

TABLE 659            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            394

TABLE 660            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER, 2023–2030 (USD MILLION)                 394

TABLE 661            GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER, 2023–2030 (USD MILLION)                 395

TABLE 662            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 395

TABLE 663            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         396

TABLE 664            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           396

TABLE 665            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         396

TABLE 666            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)         397

TABLE 667            KINGDOM OF SAUDI ARABIA: SAMPLE PREPARATION INSTRUMENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         397

TABLE 668            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         398

TABLE 669            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 398

TABLE 670            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY MARKET,

BY APPLICATION, 2023–2030 (USD MILLION)       398

TABLE 671            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     399

TABLE 672            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     399

TABLE 673            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET,

BY END USER, 2023–2030 (USD MILLION)               399

TABLE 674            KINGDOM OF SAUDI ARABIA: IMMUNOHISTOCHEMISTRY SERVICES MARKET,

BY END USER, 2023–2030 (USD MILLION)               400

TABLE 675            UAE: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            400

TABLE 676            UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            401

TABLE 677            UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            401

TABLE 678            UAE: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)                 401

TABLE 679            UAE: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)                 402

TABLE 680            UAE: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            402

TABLE 681            UAE: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            403

TABLE 682            UAE: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            403

TABLE 683            UAE: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            403

TABLE 684            UAE: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 404

TABLE 685            UAE: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 404

TABLE 686            UAE: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            404

TABLE 687            UAE: IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2023–2030 (USD MILLION)            405

TABLE 688            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2023–2030 (USD MILLION) 405

TABLE 689            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         406

TABLE 690            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           406

TABLE 691            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         406

TABLE 692            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)         407

TABLE 693            REST OF GCC COUNTRIES: SAMPLE PREPARATION INSTRUMENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         407

TABLE 694            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY REAGENTS MARKET,

BY TYPE, 2023–2030 (USD MILLION)         408

TABLE 695            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE, 2023–2030 (USD MILLION) 408

TABLE 696            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)       409

TABLE 697            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     409

TABLE 698            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     409

TABLE 699            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET,

BY END USER, 2023–2030 (USD MILLION)               410

TABLE 700            REST OF GCC COUNTRIES: IMMUNOHISTOCHEMISTRY SERVICES MARKET,

BY END USER, 2023–2030 (USD MILLION)               410

TABLE 701            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            411

TABLE 702            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY TYPE, 2023–2030 (USD MILLION)         411

TABLE 703            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY CLONALITY, 2023–2030 (USD MILLION)           411

TABLE 704            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET,

BY REGULATORY CLASS, 2023–2030 (USD MILLION)         412

TABLE 705            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)         412

TABLE 706            REST OF MIDDLE EAST: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 412

TABLE 707            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE, 2023–2030 (USD MILLION)            413

TABLE 708            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            413

TABLE 709            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION, 2023–2030 (USD MILLION)       413

TABLE 710            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     414

TABLE 711            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)     414

TABLE 712            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET,

BY END USER, 2023–2030 (USD MILLION)               414

TABLE 713            REST OF MIDDLE EAST: IMMUNOHISTOCHEMISTRY SERVICES MARKET,

BY END USER, 2023–2030 (USD MILLION)               415

TABLE 714            AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING,

2023–2030 (USD MILLION)            415

TABLE 715            AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY TYPE,

2023–2030 (USD MILLION)            416

TABLE 716            AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY CLONALITY,

2023–2030 (USD MILLION)            416

TABLE 717            AFRICA: IMMUNOHISTOCHEMISTRY ANTIBODIES MARKET, BY REGULATORY CLASS, 2023–2030 (USD MILLION)            416

TABLE 718            AFRICA: IMMUNOHISTOCHEMISTRY INSTRUMENT & SERVICES MARKET, BY TYPE, 2023–2030 (USD MILLION)            417

TABLE 719            AFRICA: SAMPLE PREPARATION INSTRUMENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            417

TABLE 720            AFRICA: IMMUNOHISTOCHEMISTRY REAGENTS MARKET, BY TYPE,

2023–2030 (USD MILLION)            418

TABLE 721            AFRICA: IMMUNOHISTOCHEMISTRY KITS MARKET, BY TYPE,

2023–2030 (USD MILLION)            418

TABLE 722            AFRICA: IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2023–2030 (USD MILLION)            418

TABLE 723            AFRICA: IMMUNOHISTOCHEMISTRY DIAGNOSTIC APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)            419

TABLE 724            AFRICA: IMMUNOHISTOCHEMISTRY RESEARCH APPLICATIONS MARKET, BY TYPE, 2023–2030 (USD MILLION)                 419

TABLE 725            AFRICA: IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2023–2030 (USD MILLION)            419

TABLE 726            AFRICA: KEY MACROINDICATORS            421

TABLE 727            OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET            422

TABLE 728            IMMUNOHISTOCHEMISTRY MARKET: DEGREE OF COMPETITION           425

TABLE 729            IMMUNOHISTOCHEMISTRY MARKET: REGION FOOTPRINT       429

TABLE 730            IMMUNOHISTOCHEMISTRY MARKET: OFFERING FOOTPRINT 430

TABLE 731            IMMUNOHISTOCHEMISTRY MARKET: APPLICATION FOOTPRINT         431

TABLE 732            IMMUNOHISTOCHEMISTRY MARKET: DETAILED LIST OF KEY STARTUP/

SME PLAYERS    434

TABLE 733            IMMUNOHISTOCHEMISTRY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY OFFERING AND REGION    435

TABLE 734            IMMUNOHISTOCHEMISTRY MARKET: PRODUCT APPROVALS,

JANUARY 2022–AUGUST 2025       438

TABLE 735            IMMUNOHISTOCHEMISTRY MARKET: DEALS, JANUARY 2022–AUGUST 2025       439

TABLE 736            IMMUNOHISTOCHEMISTRY MARKET: EXPANSIONS, JANUARY 2022–AUGUST 2025          439

TABLE 737            IMMUNOHISTOCHEMISTRY MARKET: OTHER DEVELOPMENTS,

JANUARY 2022–AUGUST 2025       440

TABLE 738            F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW          441

TABLE 739            F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED               442

TABLE 740            F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–AUGUST 2025       446

TABLE 741            DANAHER CORPORATION: COMPANY OVERVIEW          450

TABLE 742            DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED               451

TABLE 743            DANAHER CORPORATION: PRODUCT LAUNCHES AND APPROVALS,

JANUARY 2022–AUGUST 2025       455

TABLE 744            DANAHER CORPORATION: DEALS, JANUARY 2022–AUGUST 2025           456

TABLE 745            AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW          457

TABLE 746            AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED               458

TABLE 747            AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS,

JANUARY 2022–AUGUST 2025       462

TABLE 748            AGILENT TECHNOLOGIES, INC.: DEALS, JANUARY 2022–AUGUST 2025       463

TABLE 749            AGILENT TECHNOLOGIES, INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025       463

TABLE 750            PHC HOLDINGS CORPORATION: COMPANY OVERVIEW          465

TABLE 751            PHC HOLDINGS CORPORATION: PRODUCTS/SERVICES OFFERED               466

TABLE 752            PHC HOLDINGS CORPORATION: DEALS, JANUARY 2022–AUGUST 2025       471

TABLE 753            THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW          473

TABLE 754            THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED               474

TABLE 755            MERCK KGAA: COMPANY OVERVIEW     479

TABLE 756            MERCK KGAA: PRODUCTS/SERVICES OFFERED                 480

TABLE 757            BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW          489

TABLE 758            BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED               490

TABLE 759            BIO-TECHNE: COMPANY OVERVIEW      494

TABLE 760            BIO-TECHNE: PRODUCTS/SERVICES OFFERED                 495

TABLE 761            BIO-TECHNE: DEALS, JANUARY 2022–AUGUST 2025        498

TABLE 762            BIO-TECHNE: OTHER DEVELOPMENTS, JANUARY 2022–AUGUST 2025       499

TABLE 763            BECTON, DICKINSON AND COMPANY (BD): COMPANY OVERVIEW   500

TABLE 764            BECTON, DICKINSON AND COMPANY (BD): PRODUCTS/SERVICES OFFERED               501

TABLE 765            TAKARA BIO INC.: COMPANY OVERVIEW                 507

TABLE 766            TAKARA BIO INC.: PRODUCTS/SERVICES OFFERED             508

TABLE 767            ENZO BIOCHEM INC.: COMPANY OVERVIEW                 514

TABLE 768            ENZO BIOCHEM INC.: PRODUCTS/SERVICES OFFERED             515

TABLE 769            ENZO BIOCHEM INC.: EXPANSIONS, JANUARY 2022–AUGUST 2025           517

TABLE 770            SINO BIOLOGICAL, INC.: COMPANY OVERVIEW                 518

TABLE 771            SINO BIOLOGICAL, INC.: PRODUCTS/SERVICES OFFERED             518

TABLE 772            SAKURA FINETEK JAPAN CO., LTD.: COMPANY OVERVIEW          520

TABLE 773            SAKURA FINETEK JAPAN CO., LTD.: PRODUCTS/SERVICES OFFERED               520

TABLE 774            SAKURA FINETEK JAPAN CO., LTD.: PRODUCT LAUNCHES,

JANUARY 2022–AUGUST 2025       523

TABLE 775            SAKURA FINETEK JAPAN CO., LTD.: DEALS, JANUARY 2022–AUGUST 2025       524

TABLE 776            CELL SIGNALING TECHNOLOGY, INC.: COMPANY OVERVIEW   525

TABLE 777            CELL SIGNALING TECHNOLOGY, INC.: PRODUCTS/SERVICES OFFERED               525

TABLE 778            CELL SIGNALING TECHNOLOGY, INC.: DEALS, JANUARY 2022–AUGUST 2025       529

TABLE 779            BIO SB: COMPANY OVERVIEW   530

TABLE 780            BIO SB: PRODUCTS/SERVICES OFFERED                 530

TABLE 781            BIO SB: PRODUCT LAUNCHES, JANUARY 2022–AUGUST 2025     535

TABLE 782            MILTENYI BIOTEC: COMPANY OVERVIEW                 536

TABLE 783            MILTENYI BIOTEC: PRODUCTS/SERVICES OFFERED             536

TABLE 784            ORIGENE TECHNOLOGIES, INC.: COMPANY OVERVIEW          539

TABLE 785            ORIGENE TECHNOLOGIES, INC.: PRODUCTS/SERVICES OFFERED               539

TABLE 786            EAGLEBIO: COMPANY OVERVIEW            544

TABLE 787            BIOCARE MEDICAL, LLC: COMPANY OVERVIEW                 545

TABLE 788            ELABSCIENCE: COMPANY OVERVIEW    546

TABLE 789            BIOGENEX: COMPANY OVERVIEW           548

TABLE 790            DIAGNOSTIC BIOSYSTEMS INC.: COMPANY OVERVIEW          549

TABLE 791            HISTO-LINE LABORATORIES: COMPANY OVERVIEW          551

TABLE 792            ROCKLAND IMMUNOCHEMICALS, INC.: COMPANY OVERVIEW   553

TABLE 793            CANDOR BIOSCIENCE GMBH: COMPANY OVERVIEW          554

TABLE 794            GENEMED BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW   555

LIST OF FIGURES

FIGURE 1              IMMUNOHISTOCHEMISTRY MARKET SEGMENTATION & REGIONAL SCOPE    52

FIGURE 2              IMMUNOHISTOCHEMISTRY MARKET: YEARS CONSIDERED    54

FIGURE 3              IMMUNOHISTOCHEMISTRY MARKET: RESEARCH DESIGN         57

FIGURE 4              IMMUNOHISTOCHEMISTRY MARKET: BREAKDOWN OF PRIMARIES

(SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 59

FIGURE 5              IMMUNOHISTOCHEMISTRY MARKET SIZE ESTIMATION

(SUPPLY-SIDE ANALYSIS), 2024  60

FIGURE 6              IMMUNOHISTOCHEMISTRY MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH), 2024      61

FIGURE 7              COMPANY REVENUE ANALYSIS: ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE LTD. (2024)         62

FIGURE 8              IMMUNOHISTOCHEMISTRY MARKET: KEY INSIGHTS FROM PRIMARIES       63

FIGURE 9              IMMUNOHISTOCHEMISTRY SEGMENTAL MARKET SIZE ESTIMATION:

TOP-DOWN APPROACH                64

FIGURE 10            IMMUNOHISTOCHEMISTRY MARKET: CAGR PROJECTIONS   65

FIGURE 11            IMMUNOHISTOCHEMISTRY MARKET: DATA TRIANGULATION             67

FIGURE 12            IMMUNOHISTOCHEMISTRY MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION)               70

FIGURE 13            IMMUNOHISTOCHEMISTRY MARKET, BY APPLICATION,

2025 VS. 2030 (USD MILLION)      71

FIGURE 14            IMMUNOHISTOCHEMISTRY PRODUCTS MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      71

FIGURE 15            IMMUNOHISTOCHEMISTRY SERVICES MARKET, BY END USER,

2025 VS. 2030 (USD MILLION)      72

FIGURE 16            IMMUNOHISTOCHEMISTRY MARKET: REGIONAL ANALYSIS     73

FIGURE 17            GLOBAL IMMUNOHISTOCHEMISTRY MARKET SIZE, GROWTH RATE,

AND FORECAST (USD MILLION)                76

FIGURE 18            INCREASING ADOPTION OF COMPANION DIAGNOSTICS IN IMMUNOHISTOCHEMISTRY TO PROPEL MARKET GROWTH          77

FIGURE 19            US AND DIAGNOSTIC APPLICATIONS COMMANDED LARGEST NORTH AMERICAN IMMUNOHISTOCHEMISTRY MARKET SHARE IN 2024       78

FIGURE 20            HOSPITALS & DIAGNOSTIC LABORATORIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024       78

FIGURE 21            ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST CAGR DURING STUDY PERIOD              79

FIGURE 22            IMMUNOHISTOCHEMISTRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,

AND CHALLENGES          83

FIGURE 23            SHARE OF PERSONALIZED MEDICINES APPROVED BY FDA (2015–2024)  90

FIGURE 24            IMMUNOHISTOCHEMISTRY MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS                 92

FIGURE 25            AVERAGE SELLING PRICE OF INSTRUMENTS, BY KEY PLAYER, 2024 (USD)               94

FIGURE 26            AVERAGE SELLING PRICE OF KITS, BY KEY PLAYER, 2024 (USD)        94

FIGURE 27            AVERAGE SELLING PRICE OF ANTIBODIES, BY KEY PLAYER, 2024 (USD)               95

FIGURE 28            AVERAGE SELLING PRICE OF INSTRUMENTS, BY REGION, 2024 (USD MILLION)    96

FIGURE 29            AVERAGE SELLING PRICE OF KITS, BY REGION, 2024 (USD MILLION)       97

FIGURE 30            AVERAGE SELLING PRICE OF ANTIBODIES, BY REGION, 2024 (USD MILLION)    97

FIGURE 31            PATENT APPLICATIONS IN IMMUNOHISTOCHEMISTRY MARKET,

JANUARY 2014-DECEMBER 2024 101

FIGURE 32            IMMUNOHISTOCHEMISTRY MARKET: VALUE CHAIN ANALYSIS              105

FIGURE 33            IMMUNOHISTOCHEMISTRY MARKET: ECOSYSTEM ANALYSIS  107

FIGURE 34            IMMUNOHISTOCHEMISTRY MARKET: PORTER’S FIVE FORCES ANALYSIS           109

FIGURE 35            INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING              111

FIGURE 36            KEY BUYING CRITERIA FOR MAJOR END USERS                 112

FIGURE 37            US: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  116

FIGURE 38            CANADA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  117

FIGURE 39            EUROPE: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  118

FIGURE 40            JAPAN: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  119

FIGURE 41            INDIA: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  121

FIGURE 42            BRAZIL: REGULATORY PROCESS FOR IN VITRO DIAGNOSTIC DEVICES  122

FIGURE 43            FUNDING AND NUMBER OF DEALS IN IMMUNOHISTOCHEMISTRY MARKET,

2022–2025 (USD MILLION)            127

FIGURE 44            IMPACT OF AI/GEN AI ON IMMUNOHISTOCHEMISTRY MARKET     128

FIGURE 45            NORTH AMERICA: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT       271

FIGURE 46            ASIA PACIFIC: IMMUNOHISTOCHEMISTRY MARKET SNAPSHOT       326

FIGURE 47            REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET, 2020–2024 (USD MILLION)                 424

FIGURE 48            MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOHISTOCHEMISTRY MARKET (2024)        425

FIGURE 49            IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2024       428

FIGURE 50            IMMUNOHISTOCHEMISTRY MARKET: COMPANY FOOTPRINT 429

FIGURE 51            IMMUNOHISTOCHEMISTRY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024                 433

FIGURE 52            EV/EBITDA OF KEY VENDORS   436

FIGURE 53            YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY VENDORS            436

FIGURE 54            IMMUNOHISTOCHEMISTRY MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS     437

FIGURE 55            F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT          442

FIGURE 56            DANAHER CORPORATION: COMPANY SNAPSHOT          451

FIGURE 57            AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT          458

FIGURE 58            PHC HOLDINGS CORPORATION: COMPANY SNAPSHOT          466

FIGURE 59            THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT          474

FIGURE 60            MERCK KGAA: COMPANY SNAPSHOT     480

FIGURE 61            BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT          490

FIGURE 62            BIO-TECHNE: COMPANY SNAPSHOT      495

FIGURE 63            BECTON, DICKINSON AND COMPANY (BD): COMPANY SNAPSHOT   501

FIGURE 64            TAKARA BIO INC.: COMPANY SNAPSHOT                 508

FIGURE 65            ENZO BIOCHEM INC.: COMPANY SNAPSHOT                 514

MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。

※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。

ライセンス別価格表

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

ライセンスタイプ4

ミニレポート　※定性調査にフォーカスした調査レポートです。詳細はお問合せください。

ご購入に関するご案内

価格・納期について

• 価格
  • ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • マルチユーザライセンス
    • 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
  • コーポレートライセンス
    • 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
  • エンタープライズサイトライセンス
    • 特別ライセンスです。適用範囲についてはお問合せください。
• 納品形態
  • Eメール
• 納期
  • 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
• 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
• 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
• ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11

MarketsandMarkets  出版レポート一覧